GGrantIndex
← Leaderboards

Rabi Tawil

University Of Rochester

Google Scholar ↗PubMed ↗ORCID ↗
$9,728,744
Attributed
$13,848,440
Total exposure
17
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2M · FY2005–22
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22

Funding mix

By agency

NIH$12,265,553 · 16
FDA$1,582,887 · 1

By mechanism

U01$6,656,505 · 2
R01$2,471,365 · 2
P01$1,988,691 · 3
U54$1,459,364 · 1
P50$1,106,606 · 1
M01$165,909 · 8

Top collaborators

Most similar at University Of Rochester

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Research”

Research focus

Clinical ResearchClinical TrialsMuscleFutureProgramsFacioscapulohumeral Muscular DystrophyHuman SubjectInternationalSiteGenerationsResearch PersonnelGeneticEpigenetic ProcessResourcesCommunitiesMolecularSeverity Of IllnessMuscular DystrophyD4z4Muscle StrengthUniversitiesOnline SystemsParticipantEnrollment

Grant awards (59)

Resources Core$222,455
P50 · FY2022 · NS · contact PI
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD$47,505
U01 · FY2022 · NS · contact PI
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD$405,568
U01 · FY2021 · NS · contact PI
Resources Core$220,332
P50 · FY2021 · NS · contact PI
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD$550,880
U01 · FY2020 · NS · contact PI
Phase II Trial of Arimoclomol in IBM$397,836
R01 · FY2020 · FD
Resources Core$220,503
P50 · FY2020 · NS · contact PI
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD$899,778
U01 · FY2019 · NS · contact PI
Phase II Trial of Arimoclomol in IBM$399,300
R01 · FY2019 · FD
Bioresources Core: Resources for FSHD research and clinical trials$270,068
P01 · FY2019 · NS · contact PI
Resources Core$220,503
P50 · FY2019 · NS · contact PI
Biostatistics and Data Management for a Trial of Corticosteroid Regimens in DMD$204,029
U01 · FY2019 · NS
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD$778,289
U01 · FY2018 · NS · contact PI
Phase II Trial of Arimoclomol in IBM$391,250
R01 · FY2018 · FD
Resources Core$222,813
P50 · FY2018 · NS · contact PI
Bioresources Core: Resources for FSHD research and clinical trials$213,852
P01 · FY2018 · NS · contact PI
Biostatistics and Data Management for a Trial of Corticosteroid Regimens in DMD$203,615
U01 · FY2018 · NS
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD$512,058
U01 · FY2017 · NS · contact PI
Bioresources Core: Resources for FSHD research and clinical trials$266,926
P01 · FY2017 · NS · contact PI
Biostatistics and Data Management for a Trial of Corticosteroid Regimens in DMD$213,275
U01 · FY2017 · NS
Bioresources Core: Resources for FSHD research and clinical trials$267,521
P01 · FY2016 · NS · contact PI
Biostatistics and Data Management for a Trial of Corticosteroid Regimens in DMD$204,232
U01 · FY2016 · NS
Biostatistics and Data Management for a Trial of Corticosteroid Regimens in DMD$550,000
U01 · FY2015 · NS
Phase II Trial of Arimoclomol in IBM$394,501
R01 · FY2015 · FD
Bioresources Core: Resources for FSHD research and clinical trials$297,119
P01 · FY2015 · NS · contact PI
Core A Fshd Bioresources Core$30,360
P01 · FY2015 · NS · contact PI
FSHD Bioresources Core$120,437
P01 · FY2014 · NS · contact PI
FSHD Bioresources Core$118,489
P01 · FY2013 · NS · contact PI
Biostatistics and Data Management for a Trial of Corticosteroid Regimens in DMD$611,306
U01 · FY2012 · NS
FSHD Bioresources Core$122,652
P01 · FY2012 · NS · contact PI
Biostatistics and Data Management for a Trial of Corticosteroid Regimens in DMD$573,331
U01 · FY2011 · NS
FSHD Bioresources Core$123,653
P01 · FY2011 · NS · contact PI
Biostatistics and Data Management for a Trial of Corticosteroid Regimens in DMD$902,639
U01 · FY2010 · NS
FSHD Bioresources Core$157,614
P01 · FY2010 · NS · contact PI
CORE--IMAGING FACILITY$283,974
U54 · FY2007 · NS · contact PI
CORE--IMAGING FACILITY$290,380
U54 · FY2006 · NS · contact PI
CORE--IMAGING FACILITY$294,330
U54 · FY2005 · NS
POSITION EFFECT AND VASCULAR ADAPTION IN FSHD$11,129
M01 · FY2005 · RR
CORE--IMAGING FACILITY$292,429
U54 · FY2004 · NS
Position Effect and Vascular Adaption in FSHD$2,373
M01 · FY2004 · RR
CORE--IMAGING FACILITY$298,251
U54 · FY2003 · NS
INCLUSION BODY MYOSITIS: PILOT STUDY OF B-INTERFERON 1A$444,227
R01 · FY2002 · NS
DOUBLE BLIND TRIAL OF PROVENTIL IN FACIOSCAPULOHUMERAL MD$0
M01 · FY2002 · RR
QUANTITATIVE MUSCLE STRENGTH TEST--NEUROMUSCULAR DISEASE$0
M01 · FY2002 · RR
PILOT STUDY OF TOL, TOX &EFF OF BETA INTERFERON IN INCLUSION BODY MY$0
M01 · FY2002 · RR
FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD) TISSUE BANK$0
M01 · FY2002 · RR
4Q35 DELETIONS IN FSHD--IMPLICATIONS FOR DIAGNOSIS AND SEVERITY OF DISEASE$0
M01 · FY2002 · RR
INCLUSION BODY MYOSITIS: PILOT STUDY OF B-INTERFERONLA$444,251
R01 · FY2001 · NS
DOUBLE BLIND TRIAL OF PROVENTIL IN FACIOSCAPULOHUMERAL MD$19,613
M01 · FY2001 · RR
4Q35 DELETIONS IN FSHD--IMPLICATIONS FOR DIAGNOSIS AND SEVERITY OF DISEASE$19,613
M01 · FY2001 · RR
THE EFFECT OF B2 AGONIST ON MUSCLE MASS IN PROGRESSIVE MUSCLE WASTING DISORDER$19,613
M01 · FY2001 · RR
METABOLIC EFFECTS OF AN OPEN TRIAL OF PREDNISONE IN NIDDM$19,613
M01 · FY2001 · RR
DOUBLE BLIND TRIAL OF PROVENTIL IN FACIOSCAPULOHUMERAL MD$14,791
M01 · FY2000 · RR
THE EFFECT OF B2 AGONIST ON MUSCLE MASS IN PROGRESSIVE MUSCLE WASTING DISORDER$14,791
M01 · FY2000 · RR
METABOLIC EFFECTS OF AN OPEN TRIAL OF PREDNISONE IN NIDDM$14,791
M01 · FY2000 · RR
PILOT STUDY OF TOL, TOX &EFF OF BETA INTERFERON IN INCLUSION BODY MY$14,791
M01 · FY2000 · RR
4Q35 DELETIONS IN FSHD--IMPLICATIONS FOR DIAGNOSIS AND SEVERITY OF DISEASE$14,791
M01 · FY2000 · RR
QUANTITATIVE MUSCLE STRENGTH TEST--NEUROMUSCULAR DISEASE$0
M01 · FY2000 · RR
FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD) TISSUE BANK$0
M01 · FY2000 · RR